FDA warns on Internet ads.
The Food and Drug Administration has warned 14 drug makers against using brief Internet ads to promote drugs, saying the ads are misleading because they fail to provide full information about risks and indications. The ads typically appear on search engines, such as Google, as "sponsored links" when patients search for information on medical conditions. The ads cited by the FDA include promotions for the multiple sclerosis drug Tysabri (natalizumab), the cardiovascular drug Plavix (clopidogrel), and the diabetes treatment Avandia (rosiglitazone). The sponsored links generally contain only a dozen or so words--not enough to convey detailed treatment or risk information, according to the FDA. The Pew Prescription Project, a nonprofit drug-safety group, has asked the FDA to articulate the rules regulating online advertising and to advise manufacturers on where risk disclosures may appear in Internet ads.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||POLICY & PRACTICE|
|Publication:||Internal Medicine News|
|Article Type:||Brief article|
|Date:||May 1, 2009|
|Previous Article:||Massachusetts clinics are busy.|
|Next Article:||FDA seeks data on older devices.|